Literature DB >> 8386666

Autoantibodies from patients with systemic lupus erythematosus bind a shared sequence of SmD and Epstein-Barr virus-encoded nuclear antigen EBNA I.

A Sabbatini1, S Bombardieri, P Migliorini.   

Abstract

SmD is one of the small nuclear ribonucleoproteins frequently targeted by autoantibodies in systemic lupus erythematosus. We isolated and characterized the antibodies present in lupus sera that are specific for the C-terminal region of SmD (sequence 95-119). This region is highly homologous to sequence 35-58 of the EBNA I antigen, one of the nuclear antigens induced by infection with Epstein-Barr virus. Antibodies affinity purified over a peptide 95-119 column were able to recognize this sequence in the context of the whole SmD molecule, as they reacted with blotted recombinant SmD. Anti-SmD 95-119 antibodies bound also the EBNA I 35-58 peptide and detected the EBNA I molecule in a total cell extract from Epstein-Barr virus-infected lines. A population of anti-SmD antibodies is, therefore, able to bind an epitope shared by the autoantigen and the viral antigen EBNA I. To investigate the involvement of this shared epitope in the generation of anti-SmD antibodies, we immunized mice with the EBNA I 35-58 peptide. Sera from immunized animals displayed the same pattern of reactivity of spontaneously produced anti-SmD antibodies. They reacted in fact with the EBNA peptide as well as with SmD 95-119 and recombinant SmD. These data suggest that molecular mimicry may play a role in the induction of anti-SmD autoantibodies.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8386666     DOI: 10.1002/eji.1830230525

Source DB:  PubMed          Journal:  Eur J Immunol        ISSN: 0014-2980            Impact factor:   5.532


  36 in total

Review 1.  Mechanisms of viral pathogenesis in rheumatic disease.

Authors:  A Perl
Journal:  Ann Rheum Dis       Date:  1999-08       Impact factor: 19.103

2.  Induction of pathogenic anti-dsDNA antibodies is controlled on the level of B cells in a non-lupus prone mouse strain.

Authors:  Dirk Langnickel; Philipp Enghard; Claudia Klein; Reinmar Undeutsch; Berthold Hocher; R Manz; G R Burmester; Gabriela Riemekasten
Journal:  J Clin Immunol       Date:  2006-01       Impact factor: 8.317

3.  Infection in systemic lupus erythematosus: friend or foe?

Authors:  Lisa Francis; Andras Perl
Journal:  Int J Clin Rheumtol       Date:  2010-02-01

4.  Silica exposure and chronic virus infection synergistically promote lupus-like systemic autoimmunity in mice with low genetic predisposition.

Authors:  Rosana Gonzalez-Quintial; Jessica M Mayeux; Dwight H Kono; Argyrios N Theofilopoulos; Kenneth M Pollard; Roberto Baccala
Journal:  Clin Immunol       Date:  2019-06-05       Impact factor: 3.969

5.  Epigenetics in systemic lupus erythematosus: leading the way for specific therapeutic agents.

Authors:  Matlock A Jeffries; Amr H Sawalha
Journal:  Int J Clin Rheumtol       Date:  2011-08

Review 6.  The Epstein-Barr virus in autoimmunity.

Authors:  J H Vaughan
Journal:  Springer Semin Immunopathol       Date:  1995

7.  An increased prevalence of Epstein-Barr virus infection in young patients suggests a possible etiology for systemic lupus erythematosus.

Authors:  J A James; K M Kaufman; A D Farris; E Taylor-Albert; T J Lehman; J B Harley
Journal:  J Clin Invest       Date:  1997-12-15       Impact factor: 14.808

8.  Endosomal Toll-Like Receptors Mediate Enhancement of Interleukin-17A Production Triggered by Epstein-Barr Virus DNA in Mice.

Authors:  Marwa Shehab; Nour Sherri; Hadi Hussein; Noor Salloum; Elias A Rahal
Journal:  J Virol       Date:  2019-09-30       Impact factor: 5.103

9.  Anti-collagen antibodies in systemic sclerosis and in primary Raynaud's phenomenon.

Authors:  L Riente; B Marchini; M P Dolcher; A Puccetti; S Bombardieri; P Migliorini
Journal:  Clin Exp Immunol       Date:  1995-11       Impact factor: 4.330

10.  Antibodies specific for Epstein-Barr virus nuclear antigen-1 cross-react with human heterogeneous nuclear ribonucleoprotein L.

Authors:  J William Lindsey; Samantha L deGannes; Kimberly A Pate; Xiurong Zhao
Journal:  Mol Immunol       Date:  2015-11-28       Impact factor: 4.407

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.